Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12

Arthritis and Rheumatism

Volumn 56, Issue 12, 2007, Pages 4174-4181

  Wittkowski, Helmut ^a,c   Hirono, Keiichi ^b   Ichida, Fukiko ^b   Vogl, Thomas ^c   Ye, Fei ^b   Yanlin, Xing ^b   Saito, Kazuyoshi ^b   Uese, Keiichiro ^b   Miyawaki, Toshio ^b   Viemann, Dorothee ^c   Roth, Johannes ^c   Foell, Dirk ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF TOYAMA   (Japan)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; IMMUNOGLOBULIN; PROTEIN RAGE; PROTEIN S100A12; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; FEMALE; FOLLOW UP; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; LONGITUDINAL STUDIES; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS;

EID: 37149020133     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23042     Document Type: Article

References (37)

1. Burns JC. S100 proteins in the pathogenesis of Kawasaki disease. J Am Coll Cardiol 2006;48:1265-7.
2. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978;61:100-7.
3. Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005;47:305-10.
4. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease [review]. Arthritis Rheum 2004;50:3762-71.
5. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97: 889-901.
6. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
7. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2006;81:28-37.
8. Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, et al. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr 2002;58(Pt 3):407-13.
9. Xie J, Burz DS, He W, Bronstein IB, Lednev IK, Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 2006;282:4218-31.
10. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003;52:847-53.
11. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004;50:1286-95.
12. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999;71:159-70.
13. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004;279:50019-24.
14. Moser B, Hudson BI, Schmidt AM. Soluble RAGE: a hot new biomarker for the hot joint? Arthritis Res Ther 2005;7:142-4.
15. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006;13:1971-8.
16. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005;62:1734-6.
17. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725-9.
18. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-7.
19. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, et al. Circulating soluble receptor for advanced glycation end-products (sRAGE) is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-34.
20. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R817-24.
21. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al, for the Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease. Circulation 2004;110:2747-71.
22. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
23. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al, for the Italian Pediatric Rheumatology Study Group. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998;57:38-41.
24. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
25. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
26. Gu X, Chen M, Shen H, Jiang X, Huang Y, Wang H. Rv2131c gene product: an unconventional enzyme that is both inositol monophosphatase and fructose-1,6-bisphosphatase. Biochem Biophys Res Commun 2006;339:897-904.
27. Vogl T, Propper C, Hartmann M, Strey A, Strupat K, van den Bos C, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999;274:25291-6.
28. Foell D, Hernandez-Rodriguez J, Sanchez M, Vogl T, Cid MC, Roth J. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol 2004;204:311-6.
29. Hsieh HL, Schafer BW, Weigle B, Heizmann CW. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun 2004;316:949-59.
30. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003;361:1270-2.
31. Ye F, Foell D, Hirono KI, Vogl T, Rui C, Yu X, et al. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 2004;94:840-4.
32. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes [letter]. Clin Chem 2005;51:1749-50.
33. Hirono K, Foell D, Xing Y, Miyagawa-Tomita S, Ye F, Ahlmann M, et al. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol 2006;48:1257-64.
34. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via β2 integrin Mac-1. Arthritis Rheum 2006;54:3898-907.
35. Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 2004;40:1203-11.
36. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370(Pt 3):1097-109.
37. Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E, Morser J, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997;52:54-62.